Subject matter of the invention are lead-free initiating agents or initiating agent mixtures and initiating and igniting compositions which contain the lead-free initiating agents or initiating agent mixtures.

The present invention relates to: a derivative in which glutamate-urea-Lysine (GUL) and isonitrile are linked by a linker; a radioisotope labeled compound comprising the derivative; and a pharmaceutical composition for treating and diagnosing prostate cancer, containing the derivative as an active ingredient. A derivative according to the present invention has high binding capacity for PSMA, which is expressed in prostate cancer, by acting as a multi-ligand through the binding of three or six derivatives to one atom of technetium or rhenium, has excellent stability in human serum when administered in vivo, and is excreted into the kidney rather than the hepatobiliary tract because of high water solubility so that a clear image of a prostate cancer tumor site can be obtained, and thus the present invention can be effectively usable as a pharmaceutical composition for treating or diagnosing prostate cancer.

A homogeneous catalyst is provided comprising one or more metals; and at least two metal coordinating ligands wherein the homogeneous catalyst is a multi-ligand metal complex adapted for use with an oxidant in an oxidation reaction to catalytically pretreat lignocellulosic biomass. In one embodiment, the homogenous catalyst is copper (II) 2, 2′ bipyridine ethylenediamine (Cu(bpy)en). Related methods are also disclosed.

Provided are new metal complexes having phenolic and macrocyclic amino ligands as well as to their use, in particular use for bleaching catalyst for detergent compositions and oxidative crosslinking catalyst for resins, containing said metal complexes. A formulation comprises at least a detergent, a metal complex, and optionally a source of hydrogen peroxide.

[Mn.sub.3SrO.sub.4] cluster compounds are synthesized in a single step from raw materials consisting of simple and inexpensive Mn.sup.2+, Sr.sup.2+ inorganic compounds and carboxylic acids by using permanganate anion as oxidant. This step can be followed by the synthesis of asymmetric biomimetic water splitting catalyst [Mn.sub.4SrO.sub.4] cluster compounds in the presence of water. The [Mn.sub.4SrO.sub.4] cluster compound can catalyze the splitting of water in the presence of an oxidant to release oxygen gas. The neutral [Mn.sub.3SrO.sub.4](R.sub.1CO.sub.2)6(R.sub.1CO.sub.2H).sub.3 cluster compound can serve as precursors for the synthesis of biomimetic water splitting catalysts, and can be utilized in the synthesis of different types of biomimetic water splitting catalysts. [Mn.sub.4SrO.sub.4](R.sub.1CO.sub.2).sub.8(L.sub.1)(L.sub.2)(L.sub.3)(L.sub.4) cluster compounds can serve as artificial water splitting catalysts, can be utilized on the surface of an electrode or in the catalyzed splitting of water driven by an anoxidant.

Non-d.sup.0 rhenium(V) alkylidyne catalysts useful for catalyzing alkyne metathesis reactions, such as homo- and cross-metathesis of alkynes or diynes, ring closing metathesis and ring-opening metathesis, methods or use, and preparation thereof. The catalysts are stable to air and moisture and tolerate a variety of functional groups in substrates.

Compounds are described and characterized that bind guanine quadruplexes of DNA or RNA. Binding data and inhibition of growth data of five cancer cell lines are presented.

A magnetic resonance imaging (MRI) contrast agent and a preparation method and a use thereof is provided, which belong to the technical field of Magnetic Resonance Imaging contrast agent. The MRI contrast agent is prepared by the compound having a structure of formula I; and it also may include the compound having a structure of formula II or a pharmaceutically acceptable salt thereof, wherein M.sub.1 is a divalent ion or a trivalent ion of a paramagnetic metal selected from Mn, Fe, Eu, or Dy; M.sub.2 is selected from Na.sup.+, K.sup.+ or meglumine cation; when M.sub.1 is a divalent ion, a is 2; when M.sub.1 is a trivalent ion, a is 3. The MRI contrast agent has good water solubility, high relaxivity, and low toxic and side effect.

##STR00001##

A pyrazole metal complex for absorption of carbon dioxide, a method for preparing the pyrazole metal complex, and a method for absorbing carbon dioxide are provided; wherein the product produced by reacting pyrazole metal complex and carbon dioxide may be transformed into several economically valuable compounds.

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.